Replimune Group Inc

NASDAQ REPL

Data sourced from

and

Daily

Download Data

Replimune Group Inc Market Capitalization on June 03, 2024: USD 334.10 M

Replimune Group Inc Market Capitalization is USD 334.10 M on June 03, 2024, a -74.89% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Replimune Group Inc 52-week high Market Capitalization is USD 1.42 B on June 13, 2023, which is 324.65% above the current Market Capitalization.
Replimune Group Inc 52-week low Market Capitalization is USD 307.69 M on May 29, 2024, which is -7.90% below the current Market Capitalization.
Replimune Group Inc average Market Capitalization for the last 52 weeks is USD 761.34 M.

NASDAQ: REPL

Replimune Group Inc

CEO	Mr. Philip Astley-Sparke FSA
IPO Date	July 20, 2018
Location	United States
Headquarters	500 Unicorn Park Drive, Woburn, MA, United States, 01801
Employees	331
Sector	Healthcare
Industry	Biotechnology

Description

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Key trends